Selective manipulation of aging: A novel strategy for the treatment of neurodegenerative disorders

Swiss Medical Weekly

Volumn 144, Issue , 2014, Pages

  Moll, Lorna ^a   El Ami, Tayir ^a   Cohen, Ehud ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Aging; Insulin IGF signalling; Neurodegenerative disorders; Proteostasis; Proteotoxicity

Indexed keywords

AMYLOID BETA PROTEIN; ATAXIN 3; HEAT SHOCK TRANSCRIPTION FACTOR 1; HUNTINGTIN; INSULIN; POLYGLUTAMINE; SOMATOMEDIN; TRANSCRIPTION FACTOR FOXO; SOMATOMEDIN C;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; FAMILIAL DISEASE; GENE MUTATION; HUNTINGTON CHOREA; MACHADO JOSEPH DISEASE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PREMATURITY; PRION DISEASE; PROTEIN AGGREGATION; PROTEIN HOMEOSTASIS; RESPIRATORY CHAIN; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; DRUG ANTAGONISM; GENETICS; HOMEOSTASIS; HUMAN; METABOLISM; PHYSIOLOGY;

AGING; ANIMALS; BRAIN; HOMEOSTASIS; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION;

EID: 84899729969     PISSN: 14247860     EISSN: 14243997     Source Type: Journal    
DOI: 10.4414/smw.2014.13917     Document Type: Review

References (78)

1. Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature. 2011;475:324-32.
2. Ciechanover A. The ubiquitin proteolytic system: from a vague idea, through basic mechanisms, and onto human diseases and drug targeting. Neurology. 2006;66:S7-19.
3. Wong E, Cuervo AM. Autophagy gone awry in neurodegenerative diseases. Nat Neurosci. 2010;13:805-11.
4. Balch WE, Morimoto RI, Dillin A, Kelly JW. Adapting proteostasis for disease intervention. Science. 2008;319:916-9. (Pubitemid 351263754)
5. Kaganovich D, Kopito R, Frydman J. Misfolded proteins partition between two distinct quality control compartments. Nature. 2008;454:1088-95.
6. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;31:805-10. (Pubitemid 39434070)
7. Ben-Gedalya T, Cohen E. Quality control compartments coming of age. Traffic. 2012;13:635-42.
8. Kopito RR, Ron D. Conformational disease. Nat Cell Biol. 2000;2:E207-209.
9. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci. 2003;4:49-60. (Pubitemid 37271088)
10. Selkoe DJ. Alzheimer's disease. Cold Spring Harb Perspect Biol. 2011;3(7).
11. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837-42.
12. O'Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, et al. Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci. 2010;30:14411-9.
13. Campion D, Flaman JM, Brice A, Hannequin D, Dubois B, Martin C, et al. Mutations of the presenilin/gene in families with early-onset Alzheimer's disease. Hum Mol Genet. 1995;4:2373-7.
14. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488(7409):96-9.
15. Chavez-Gutierrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, et al. The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. Embo J. 2012;31:2261-74.
16. Shen J, Kelleher RJ, 3rd. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A 2007;104:403-9. (Pubitemid 46123039)
17. Coen K, Flannagan RS, Baron S, Carraro-Lacroix LR, Wang D, et al. Lysosomal calcium homeostasis defects, not proton pump defects, cause endo-lysosomal dysfunction in PSEN-deficient cells. J Cell Biol. 2012;198:23-35.
18. Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell. 2010;141:1146-58.
19. Area-Gomez E, Del Carmen Lara Castillo M, Tambini MD, Guardia-Laguarta C, de Groof AJ, et al. Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. Embo J. 2012;31:4106-23.
20. Bates G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet. 2003;361:1642-4. (Pubitemid 36579005)
21. Durcan TM, Fon EA. Ataxin-3 and its e3 partners: implications for machado-joseph disease. Front Neurol. 2013;4:46.
22. Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci. 2013;14:248-64.
23. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130-3. (Pubitemid 44547757)
24. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59-62. (Pubitemid 23087289)
25. Amaducci L, Tesco G. Aging as a major risk for degenerative diseases of the central nervous system. Curr Opin Neurol. 1994;7:283-6. (Pubitemid 24243729)
26. Gems D, Partridge L. Genetics of longevity in model organisms: debates and paradigm shifts. Annu Rev Physiol. 2013;75:621-44.
27. McCay CM, Crowell MF, Maynard LA. The effect of retarded growth upon the length of life span and upon the ultimate body size. 1935. Nutrition 1989;5:155-71; discussion 172.
28. Mair W, Dillin A. Aging and Survival: The Genetics of Life Span Extension by Dietary Restriction. Annu Rev Biochem. 2008;77:727-54.
29. Bishop NA, Guarente L. Two neurons mediate diet-restriction-induced longevity in C. elegans. Nature. 2007;447:545-9. (Pubitemid 46868049)
30. Panowski SH, Wolff S, Aguilaniu H, Durieux J, Dillin A. PHA-4/Foxa mediates diet-restriction-induced longevity of C. elegans. Nature. 2007;447:550-5. (Pubitemid 46868041)
31. Dillin A, Hsu AL, Arantes-Oliveira N, Lehrer-Graiwer J, Hsin H, et al. Rates of behavior and aging specified by mitochondrial function during development. Science. 2002;298:2398-401. (Pubitemid 36014215)
32. Feng J, Bussiere F, Hekimi S. Mitochondrial electron transport is a key determinant of life span in Caenorhabditis elegans. Dev Cell. 2001;1:633-44. (Pubitemid 33586116)
33. Durieux J, Wolff S, Dillin A. The cell-non-autonomous nature of electron transport chain-mediated longevity. Cell. 2011;144:79-91.
34. Giannakou ME, Goss M, Jacobson J, Vinti G, Leevers SJ, et al. Dynamics of the action of dFOXO on adult mortality in Drosophila. Aging Cell. 2007;6(4):429-38.
35. Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R. A C. elegans mutant that lives twice as long as wild type. Nature. 1993;366:461-4. (Pubitemid 24013878)
36. Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature. 2003;421:182-7. (Pubitemid 36090987)
37. Lee RY, Hench J, Ruvkun G. Regulation of C. elegans DAF-16 and its human ortholog FKHRL1 by the daf-2 insulin-like signaling pathway. Curr Biol. 2001;11:1950-7. (Pubitemid 33146421)
38. Tullet JM, Hertweck M, An JH, Baker J, Hwang JY, et al. Direct inhibition of the longevity-promoting factor SKN-1 by insulin-like signaling in C. elegans. Cell. 2008;132:1025-38. (Pubitemid 351391953)
39. Chiang WC, Ching TT, Lee HC, Mousigian C, Hsu AL. HSF-1 Regulators DDL-1/2 Link Insulin-like Signaling to Heat-Shock Responses and Modulation of Longevity. Cell. 2012;148:322-34.
40. Tepper RG, Ashraf J, Kaletsky R, Kleemann G, Murphy CT, et al. PQM-1 Complements DAF-16 as a Key Transcriptional Regulator of DAF-2-Mediated Development and Longevity. Cell. 2013;154:676-90.
41. Kenyon C. The plasticity of aging: insights from long-lived mutants. Cell. 2005;120:449-60. (Pubitemid 40269760)
42. Kimura KD, Tissenbaum HA, Liu Y, Ruvkun G. daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science. 1997;277:942-6. (Pubitemid 27366677)
43. Partridge L, Bruning JC. Forkhead transcription factors and ageing. Oncogene. 2008;27:2351-63. (Pubitemid 351501786)
44. Selman C, Lingard S, Choudhury AI, Batterham RL, Claret M, et al. Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice. Faseb J. 2008;22:807-18. (Pubitemid 351348133)
45. Flachsbart F, Caliebe A, Kleindorp R, Blanche H, von Eller-Eberstein H, et al. Association of FOXO3A variation with human longevity confirmed in German centenarians. Proc Natl Acad Sci U S A 2009;106:2700-5.
46. Suh Y, Atzmon G, Cho MO, Hwang D, Liu B, et al. Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc Natl Acad Sci U S A. 2008;105:3438-42. (Pubitemid 351723571)
47. Willcox BJ, Donlon TA, He Q, Chen R, Grove JS, et al. FOXO3A genotype is strongly associated with human longevity. Proc Natl Acad Sci U S A. 2008;105:13987-92.
48. McElwee J, Bubb K, Thomas JH. Transcriptional outputs of the Caenorhabditis elegans forkhead protein DAF-16. Aging Cell. 2003;2:111-21.
49. Murphy CT, McCarroll SA, Bargmann CI, Fraser A, Kamath RS, et al. Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature. 2003;424:277-83.
50. Halaschek-Wiener J, Khattra JS, McKay S, Pouzyrev A, Stott JM, et al. Analysis of long-lived C. elegans daf-2 mutants using serial analysis of gene expression. Genome Res. 2005;15:603-15. (Pubitemid 41043631)
51. Oh SW, Mukhopadhyay A, Dixit BL, Raha T, Green MR, et al. Identification of direct DAF-16 targets controlling longevity, metabolism and diapause by chromatin immunoprecipitation. Nat Genet. 2006;38:251-7. (Pubitemid 43177243)
52. Dong MQ, Venable JD, Au N, Xu T, Park SK, et al. Quantitative mass spectrometry identifies insulin signaling targets in C. elegans. Science. 2007;317:660-3. (Pubitemid 47229964)
53. Morley JF, Brignull HR, Weyers JJ, Morimoto RI. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2002;99:10417-22.
54. Link C. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci U S A. 1995;92:9368-72.
55. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A. Opposing activities protect against age-onset proteotoxicity. Science. 2006;313:1604-10. (Pubitemid 44414028)
56. Cohen E, Du D, Joyce D, Kapernick EA, Volovik Y, et al. Temporal requirements of insulin/IGF-1 signaling for proteotoxicity protection. Aging Cell. 2010;9:126-34.
57. Steinkraus KA, Smith ED, Davis C, Carr D, Pendergrass WR, et al. Dietary restriction suppresses proteotoxicity and enhances longevity by an hsf-1-dependent mechanism in Caenorhabditis elegans. Aging Cell. 2008;7:394-404. (Pubitemid 351663908)
58. Mouton PR, Chachich ME, Quigley C, Spangler E, Ingram DK. Caloric restriction attenuates amyloid deposition in middle-aged dtg APP/PS1 mice. Neurosci Lett. 2009;464:184-7.
59. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602-11. (Pubitemid 44708852)
60. Zhang T, Mullane PC, Periz G, Wang J. (2011) TDP-43 neurotoxicity and protein aggregation modulated by heat shock factor and insulin/IGF-1 signaling. Hum Mol Genet.
61. Boccitto M, Lamitina T, Kalb RG. Daf-2 signaling modifies mutant SOD1 toxicity in C. elegans. PLoS One. 2012;7:e33494.
62. Teixeira-Castro A, Ailion M, Jalles A, Brignull HR, Vilaca JL, et al. (2011) Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: rescue by the DAF-16 and HSF-1 pathways. Hum Mol Genet. 2011;20(15):2996-3009.
63. Killick R, Scales G, Leroy K, Causevic M, Hooper C, et al. Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem Biophys Res Commun. 2009;386:257-62.
64. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99-102. (Pubitemid 26332733)
65. Freude S, Hettich MM, Schumann C, Stohr O, Koch L, et al. Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. Faseb J. 2009;23:3315-24.
66. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, et al. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 2001;17:157-65. (Pubitemid 32409891)
67. Reiserer RS, Harrison FE, Syverud DC, McDonald MP. Impaired spatial learning in the APPSwe + PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav. 2007;6:54-65. (Pubitemid 46090333)
68. Cohen E, Paulsson JF, Blinder P, Burstyn-Cohen T, Du D, et al. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell. 2009;139:1157-69.
69. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101-12. (Pubitemid 46432529)
70. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med. 2002;8:1390-7. (Pubitemid 36019424)
71. Poirier R, Fernandez AM, Torres-Aleman I, Metzger F. Early brain amyloidosis in APP/PS1 mice with serum insulin-like growth factor-I deficiency. Neurosci Lett. 2012;509:101-4.
72. Fernandez AM, Torres-Aleman I. The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci. 2012;13:225-39.
73. Carro E, Trejo JL, Gerber A, Loetscher H, Torrado J, et al. Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol Aging. 2006;27:1250-7. (Pubitemid 44088577)
74. Calamini B, Silva MC, Madoux F, Hutt DM, Khanna S, et al. Small-molecule proteostasis regulators for protein conformational diseases. Nat Chem Biol. 2012;8:185-96.
75. Honda Y, Tanaka M, Honda S. Trehalose extends longevity in the nematode Caenorhabditis elegans. Aging Cell. 2010;9:558-69.
76. Alavez S, Vantipalli MC, Zucker DJ, Klang IM, Lithgow GJ. Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan. Nature. 2011;472:226-9.
77. Mojsilovic-Petrovic J, Nedelsky N, Boccitto M, Mano I, Georgiades SN, et al. FOXO3a is broadly neuroprotective in vitro and in vivo against insults implicated in motor neuron diseases. J Neurosci. 2009;29:8236-47.
78. El-Ami T, Moll L, Marques CF, Volovik Y, Reuveni H, et al. (2013) A Novel Inhibitor of the Insulin/IGF Signaling Pathway Protects from Age-Onset, Neurodegeneration-linked Proteotoxicity. Aging Cell. 2014;13(1):165-74.